Novan Inc. (NOVN)

$0.03

up-down-arrow $0.01 (33.46%)

As on 26-Sep-2023 09:30EDT

Market cap

info icon

$3 Mln

Revenue (TTM)

info icon

$25 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

5.1

Div. Yield

info icon

0 %

Novan (NOVN) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 0.03 High: 0.04

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-29 Mln

  • ROEROE information

    -21 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    29.94

  • EV/EBITDAEV/EBITDA information

    -0.7

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    28,015,400

9 Years Aggregate

CFO

$-245.04 Mln

EBITDA

$-272.35 Mln

Net Profit

$-258.29 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Novan (NOVN)
-97.6 -30.6 -91.7 -98.0 -81.0 -73.5 --
BSE Sensex*
-10.2 -0.9 -7.6 -7.0 7.1 8.5 11.4
As on 26-Sep-2023  |  *As on 26-May-2026
Company
2022
2021
2020
2019
2018
2017
Novan (NOVN)
-65.0 -48.7 -74.3 280.7 -80.2 -84.4
BSE Sensex
4.4 22.0 15.8 14.4 5.9 27.9
BSE Sensex
4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Novan (NOVN)
0.0 2.6 24.7 1.0 -144.2 -- -- 5.1
12.6 3,962.3 3,045.9 122.4 13.8 -- 33.6 105.4
41.0 5,252.7 1,105.3 133.3 15.9 32.7 38.3 12.7
235.0 12,143.0 708.2 -188.3 -25.6 -293.5 -- 222.5
67.0 13,537.9 580.0 -725.9 -105.2 -- -- 123.7
31.3 3,825.6 597.0 221.3 46.1 22.9 18.1 3.8
59.7 6,464.7 769.1 47.9 5.4 7.5 172.1 10.0
22.5 10,853.0 4,893.0 -242.0 -1.5 -3.7 -- 1.7
231.3 4,596.0 274.5 153.6 76.6 15.8 29.9 4.6
59.7 5,422.8 288.1 22.3 17.5 34.1 358.7 49.9

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Novan (NOVN)

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris;...  SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.  Read more

  • Pres, CEO & Chairwoman

    Ms. Paula Brown Stafford M.P.H.

  • Pres, CEO & Chairwoman

    Ms. Paula Brown Stafford M.P.H.

  • Headquarters

    Durham, NC

  • Website

    https://www.novan.com

Edit peer-selector-edit
loading...
loading...

FAQs for Novan (NOVN)

The share price of Novan Inc (NOVN) is $0.03 (NASDAQ) as of 26-Sep-2023 09:30 EDT. Novan Inc (NOVN) has given a return of -80.99% in the last 3 years.

Since, TTM earnings of Novan Inc (NOVN) is negative, P/E ratio is not available.
The P/B ratio of Novan Inc (NOVN) is 5.10 times as on 26-Sep-2023, a 16 discount to its peers’ median range of 6.06 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2022
--
--
2021
--
--
2020
--
--
2019
--
--
2018
--
--

The 52-week high and low of Novan Inc (NOVN) are Rs -- and Rs -- as of 26-May-2026.

Novan Inc (NOVN) has a market capitalisation of $ 3 Mln as on 26-Sep-2023. As per SEBI classification, it is a company.

Before investing in Novan Inc (NOVN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.